<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117439</url>
  </required_header>
  <id_info>
    <org_study_id>100452</org_study_id>
    <nct_id>NCT03117439</nct_id>
  </id_info>
  <brief_title>Beta-Glucan Driven vs. Empirical Antifungal Therapy in Critically Ill Patients</brief_title>
  <official_title>(1-3)-Beta-D-Glucan Driven vs. Empirical Antifungal Therapy in High Risk Critically Ill Patients A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to compare the duration of standard anti fungal therapy in high risk ICU
      patients with a strategy driven by BetaDGlucan test result
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of anti fungal duration in the Beta Glucan group compared with standard empirical approach</measure>
    <time_frame>First 30 days from enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure of Invasive Canididiasis</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological eradication of Invasive Candidiasis</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Any cause ICU mortality within three months from enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Any cause hospital mortality within three months from enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU length of stay</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of invasive Candida Infections and Beta-Glucan accuracy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost evaluation (empirical anti fungal therapy vs. Beta Glucan test)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Antifungal Agents</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1-3 Beta-D-Glucan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>duration of antifungal therapy</intervention_name>
    <description>Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test</description>
    <arm_group_label>1-3 Beta-D-Glucan Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICU admission (minimum of 48 hours in ICU with an expected length of stay of at least
             48 hours)

          -  Ongoing Mechanical Ventilation

          -  Presence of CVC

          -  Sepsis/Septic Shock development while receiving broad spectrum antibiotics

          -  Positivity of Candida Score or Candida Colonization Index in absence of septic shock

        Exclusion Criteria:

          -  Complicated Candida Infection

          -  Already ongoing anti fungal therapy

          -  Beta Glucan test not available

          -  Absence of informed consent

          -  Immunesuppressive status (long-term immunesuppresive or steroids therapy; AIDS; WBC
             &lt;1000/mmc or neutrophils &lt;500/mmc)

          -  Pregnancy

          -  Already enrolled in other interventional studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gennaro De Pascale</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

